Psammaplin A inhibits hepatitis C virus NS3 helicase

Journal of Natural Medicines

Volumn 67, Issue 4, 2013, Pages 765-772

  Salam, Kazi Abdus ^a   Furuta, Atsushi ^b,c   Noda, Naohiro ^b,c   Tsuneda, Satoshi ^b   Sekiguchi, Yuji ^c   Yamashita, Atsuya ^d   Moriishi, Kohji ^d   Nakakoshi, Masamichi ^e   Tsubuki, Masayoshi ^e   Tani, Hidenori ^c   Tanaka, Junichi ^a,f   Akimitsu, Nobuyoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

^e HOSHI UNIVERSITY   (Japan)

^f UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Hepatitis C virus; NS3 RNA helicase; Photo induced electron transfer; Psammaplin A

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTIVIRUS AGENT; ENZYME INHIBITOR; NS3 HELICASE; PSAMMAPLIN A; RNA HELICASE; SINGLE STRANDED RNA; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; ELECTRON TRANSPORT; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; GENOTYPE; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; IC 50; MARINE SPECIES; MEDIAN EFFECTIVE CONCENTRATION; NONHUMAN; REPLICON; VIRUS INHIBITION; VIRUS REPLICATION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DISULFIDES; HEPACIVIRUS; RNA; RNA HELICASES; TYROSINE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84884202160     PISSN: 13403443     EISSN: 18610293     Source Type: Journal    
DOI: 10.1007/s11418-013-0742-7     Document Type: Article

References (41)

1. Gravitz L (2011) Introduction: A smouldering public-health crisis. Nature 474:S2-S4
2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45:529-538
3. Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z (2010) Hepatitis C treatment: current and future perspectives. Virol J 7:1-6
4. Lemon SM, McKeating JA, Pietschmann T, Frick DN, Glenn JS, Tellinghuisen TL, Symons J, Furman PA (2010) Development of novel therapies for hepatitis C. Antiviral Res 86:79-92
5. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362
6. Takamizawa A, Mori C, Fuke I, Manabe S, Murakami S, Fujita J, Onishi E, Anodoh T, Yoshida I, Oakayama H (1991) Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 65:1105-1113
7. Kai L (2010) Development of novel antiviral therapies for hepatitis C virus. Virol Sin 25:246-266
8. Moradpour D, Penin F, Rice CM (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5:453-463
9. Rice CM (2011) New insights into HCV replication: potential antiviral targets. Top Antivir Med 19:117-120
10. De Francesco R, Steinkühler C (2000) Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr Top Microbiol Immunol 242:149-169
11. Raney KD, Sharma SD, Moustafa IM, Cameron CE (2010) Hepatitis C virus non-structural protein 3 (HCV NS3): a multifunctional antiviral target. J Biol Chem 285:22725-22731
12. Burney T, Dusheiko G (2011) Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Rev Anti-Infect Ther 9:151-160
13. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207-1217
14. Arabshahi L, Schmitz FJ (1987) Brominated tyrosine metabolites from an unidentified sponge. J Org Chem 52:3584-3586
15. Quiñoà E, Crews P (1987) Phenolic constituents of psammaplysilla. Tetrahedron Lett 28:3229-3232
16. Tani H, Akimitsu N, Fujita O, Matsuda Y, Miyata R, Tsuneda S, Igarashi M, Sekiguchi Y, Noda N (2009) High-throughput screening assay of hepatitis C virus helicase inhibitors using fluorescence-quenching phenomenon. Biochem Biophys Res Commun 379:1054-1059
17. Salam KA, Furuta A, Noda N, Tsuneda S, Sekiguchi Y, Yamashita A, Moriishi K, Nakakoshi M, Tsubuki M, Tani H, Tanaka J, Akimitsu N (2012) Inhibition of hepatitis C virus NS3 helicase by manoalide. J Nat Prod 75:650-654
18. Yamashita A, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Fujita Y, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Tanaka J, Moriishi K (2012) Inhibition of hepatitis C virus replication and viral helicase by ethyl acetate extract of the marine feather star Alloeocomatella polycladia. Mar Drugs 10:744-761
19. Frese M, Barth K, Kaul A, Lohmann V, Schwärzle V, Bartenschlager R (2003) Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha. J Gen Virol 84:1253-1259
20. Nishimura-Sakurai Y, Sakamoto N, Mogushi K, Nagaie S, Nakagawa M, Itsui Y, Tasaka-Fujita M, Onuki-Karakama Y, Suda G, Mishima K, Yamamoto M, Ueyama M, Funaoka Y, Watanabe T, Azuma S, Sekine-Osajima Y, Kakinuma S, Tsuchiya K, Enomoto N, Tanaka H, Watanabe M (2010) Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells. J Gastroenterol 45:523-536
21. Suzich JA, Tamura JK, Palmer-Hill F, Warrener P, Grakoui A, Rice CM, Feinstone SM, Collett MS (1993) Hepatitis C virus NS3 protein polynucleotide-stimulated nucleoside triphosphatase and comparison with the related pestivirus and flavivirus enzymes. J Virol 67:6152-6158
22. Borowski P, Deinert J, Schalinski S, Bretner M, Ginalski K, Kulikowski T, Shugar D (2003) Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur J Biochem 270:1645-1653
23. Gu M, Rice CM (2010) Three conformational snapshots of the hepatitis C virus NS3 helicase reveal a ratchet translocation mechanism. Proc Nat Acad Sci USA 107:521-528
24. Senisterra GA, Hong BS, Park HW, Vedadi M (2008) Application of high-throughput isothermal denaturation to assess protein stability and screen for ligands. J Biomol Screen 13:337-342
25. Sarver RW, Rogers JM, Stockman BJ, Epps DE, DeZwaan J, Harris MS, Baldwin ET (2002) Physical methods to determine the binding mode of putative ligands for hepatitis C virus NS3 helicase. Anal Biochem 309:186-195
26. Jung JH, Sim CJ, Lee C-O (1995) Cytotoxic compounds from a two-sponge association. J Nat Prod 58:1722-1726
27. Kim D, Lee IS, Jung JH, Yang SI (1999) Psammaplin A, a natural bromotyrosine derivative from a sponge, possesses the antibacterial activity against methicillin-resistant Staphylococcus aureus and the DNA gyrase-inhibitory activity. Arch Pharm Res 22:25-29
28. Kim D, Lee IS, Jung JH, Lee CO, Choi SU (1999) Psammaplin A, a natural phenolic compound, has inhibitory effect on human topoisomerase II and is cytotoxic to cancer cells. Anticancer Res 19:4085-4090
29. Nicholas GM, Eckman LL, Ray S, Hughes RO, Pfefferkorn JA, Barluenga S, Nicolaou KC, Bewley CA (2002) Bromotyrosine-derived natural and synthetic products as inhibitors of mycothiol-S-conjugate amidase. Bioorg Med Chem Lett 12:2487-2490
30. Tabudravu JN, Eijsink VG, Gooday GW, Jaspars M, Komander D, Legg M, Synstad B, van Aalten DM (2002) Psammaplin A, a chitinase inhibitor isolated from the Fijian marine sponge Aplysinella rhax. Bioorg Med Chem 10:1123-1128
31. Jiang Y, Ahn EY, Ryu SH, Kim DK, Park JS, Yoon HJ, You S, Lee BJ, Lee DS, Jung JH (2004) Cytotoxicity of psammaplin A from a two-sponge association may correlate with the inhibition of DNA replication. BMC Cancer 4:1-8
32. Fajas L, Egler V, Reiter R, Hansen J, Kristiansen K, Debril MB, Miard S, Auwerx J (2002) The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell 3:903-910
33. Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J (2003) PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene 22:4186-4193
34. Fu M, Rao M, Bouras T, Wang C, Wu K, Zhang X, Li Z, Yao TP, Pestell RG (2005) Cyclin D1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipogenesis through histone deacetylase recruitment. J Biol Chem 280:16934-16941
35. Mora FD, Jones DK, Desai PV, Patny A, Avery MA, Feller DR, Smillie T, Zhou YD, Nagle DG (2006) Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells. J Nat Prod 69:547-552
36. Shim JS, Lee HS, Shin J, Kwon HJ (2004) Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett 203:163-169
37. Shin J, Lee H-S, Seo Y, Rho J-R, Cho KW, Paul VJ (2000) New bromotyrosine metabolites from the sponge Aplysinella rhax. Tetrahedron 56:9071-9077
38. Piña IC, Gautschi JT, Wang GY, Sanders ML, Schmitz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski SW, Perez LB, Bair KW, Crews P (2003) Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 68:3866-3873
39. Diana GD, Bailey TR (1997) Compounds, compositions and methods for treatment of hepatitis C. U.S. Patent 5,633,388
40. Chen CS, Chiou CT, Chen GS, Chen SC, Hu CY, Chi WK, Chu YD, Hwang LH, Chen PJ, Chen DS, Liaw SH, Chern JW (2009) Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase. J Med Chem 52:2716-2723
41. Janetka, JW, Ledford BE, Mullican MD (2000). Pentacyclic compounds useful as inhibitors of hepatitis C virus NS3 helicase. Patent WO 00/24725